Shopping Cart 0
Cart Subtotal
USD 0

Aduro BioTech Inc (ADRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Aduro BioTech Inc (Aduro BioTech) is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products under development are intended for the treatment of multiple indications, including pancreatic, lung, ovarian, prostate cancers, mesothelioma and glioblastoma. The company collaborates with various pharmaceutical companies to expand its products and technology platforms. Aduro BioTech is headquartered in Berkeley, California, the US.

Aduro BioTech Inc (ADRO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aduro BioTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13

Venture Financing 15

Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15

Aduro BioTech Raises USD55 Million in Series C Financing 17

Aduro BioTech Raises USD 7 Million In Venture Financing 18

Aduro BioTech Raises USD 6.5 Million In Venture Financing 19

BioNovion Raises Funds through Venture Financing 20

Partnerships 21

Aduro BioTech Enters into Agreement with Immunotherapeutics and Vaccine Research Initiative 21

HitGen Enters into Agreement with Aduro Biotech 22

Aduro Biotech Expands Agreement with Merck 23

University of California, Berkeley Enters into Agreement with Aduro Biotech 24

Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 25

BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 26

Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 27

Licensing Agreements 29

Aduro BioTech Enters into Licensing Agreement with Stanford University 29

Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 30

Merck Enters into Licensing Agreement with BioNovion 31

Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 32

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 34

Aduro BioTech Enters Into Licensing Agreement With University Of California, Berkeley 35

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 36

Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University for GVAX-Related Patent Rights 37

Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 38

Aduro BioTech Enters into Licensing Agreement with UCB 39

Equity Offering 40

Aduro Biotech Plans to Raise Funds through Public Offering of Shares 40

Aduro Biotech Plans to Raise up to USD100 Million in Public Offering of Shares 41

Aduro Biotech to Raise up to USD100 Million in Public Offering of Shares 42

Aduro BioTech Raises USD25 Million in Private Placement Shares 43

Aduro BioTech Raises USD136.8 Million in IPO 44

Acquisition 46

Aduro Biotech Acquires BioNovion 46

Aduro BioTech Inc-Key Competitors 47

Aduro BioTech Inc-Key Employees 48

Aduro BioTech Inc-Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Recent Developments 50

Financial Announcements 50

Oct 30, 2018: Aduro Biotech reports third quarter 2018 financial results 50

Aug 01, 2018: Aduro Biotech reports second quarter 2018 financial results 51

May 02, 2018: Aduro Biotech Announces First Quarter 2018 Financial Results 52

Mar 01, 2018: Aduro Biotech Reports Fourth Quarter And Full Year 2017 Financial Results 53

Oct 31, 2017: Aduro Biotech Reports Third Quarter 2017 Financial Results 54

Aug 02, 2017: Aduro Biotech Reports Second Quarter 2017 Financial Results 55

May 02, 2017: Aduro Biotech Reports First Quarter 2017 Financial Results 56

Mar 01, 2017: Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results 57

Corporate Communications 59

Sep 19, 2018: Aduro Biotech Announces the Departure of Natalie R. Sacks 59

Jan 05, 2018: Aduro Biotech Announces Management Changes 60

Jul 27, 2017: Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017 61

Apr 20, 2017: Aduro Biotech Announces Management Promotions 62

Product News 63

12/18/2017: Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma 63

12/12/2017: Aduro Biotech Provides Update on CRS-207 Programs 64

09/04/2018: Aduro Biotech and Dana-Farber Cancer Institute publish data highlighting immunosuppressive impact of APRIL in multiple myeloma in leukemia 65

03/06/2017: Aduro Biotech Presents Data On BION-1301 at the 2017 American Association for Cancer Research Annual Meeting 66

03/06/2017: Aduro Biotech Presents Data on Vaccine Technology targeting STING at the 2017 American Association for Cancer Research Annual Meeting 67

Clinical Trials 68

Sep 04, 2018: Aduro Biotech presents preclinical data for BION-1301, a first-in-class antibody targeting human APRIL, at the 2018 European Congress of Immunology 68

Apr 17, 2018: Aduro Biotech Presents Preclinical Data of ADU-1604 at the American Association for Cancer Research Annual Meeting 69

Apr 17, 2018: Aduro Biotech Presents Preclinical Data of BION-1301 at the American Association for Cancer Research Annual Meeting 70

Mar 14, 2018: Aduro Biotech to Present Preclinical Data on ADU-1604 at AACR 2018 Annual Meeting 71

Mar 14, 2018: Aduro Biotech to Present Preclinical Data on BION-1301 at AACR 2018 Annual Meeting 72

Nov 10, 2017: Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604 73

Nov 01, 2017: Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting 74

Sep 27, 2017: Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology 75

Aug 09, 2017: Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents 76

Jun 29, 2017: Aduro Biotech Announces Initiation of Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Previously-Treated Gastroesophageal Adenocarcinoma 77

Jun 28, 2017: Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA for the Treatment of Patients with Previously Treated Malignant Pleural Mesothelioma 78

May 26, 2017: Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting 79

Appendix 80

Methodology 80

About GlobalData 80

Contact Us 80

Disclaimer 80


List Of Figure

List of Figures

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aduro BioTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aduro BioTech Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13

Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15

Aduro BioTech Raises USD55 Million in Series C Financing 17

Aduro BioTech Raises USD 7 Million In Venture Financing 18

Aduro BioTech Raises USD 6.5 Million In Venture Financing 19

BioNovion Raises Funds through Venture Financing 20

Aduro BioTech Enters into Agreement with Immunotherapeutics and Vaccine Research Initiative 21

HitGen Enters into Agreement with Aduro Biotech 22

Aduro Biotech Expands Agreement with Merck 23

University of California, Berkeley Enters into Agreement with Aduro Biotech 24

Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 25

BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 26

Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 27

Aduro BioTech Enters into Licensing Agreement with Stanford University 29

Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 30

Merck Enters into Licensing Agreement with BioNovion 31

Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 32

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 34

Aduro BioTech Enters Into Licensing Agreement With University Of California, Berkeley 35

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 36

Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University for GVAX-Related Patent Rights 37

Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 38

Aduro BioTech Enters into Licensing Agreement with UCB 39

Aduro Biotech Plans to Raise Funds through Public Offering of Shares 40

Aduro Biotech Plans to Raise up to USD100 Million in Public Offering of Shares 41

Aduro Biotech to Raise up to USD100 Million in Public Offering of Shares 42

Aduro BioTech Raises USD25 Million in Private Placement Shares 43

Aduro BioTech Raises USD136.8 Million in IPO 44

Aduro Biotech Acquires BioNovion 46

Aduro BioTech Inc, Key Competitors 47

Aduro BioTech Inc, Key Employees 48

Aduro BioTech Inc, Other Locations 49

Aduro BioTech Inc, Subsidiaries 49

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Aduro BioTech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Aduro BioTech Inc (Aduro BioTech) is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products under development are intended for the treatment of multiple indications, including pancreatic, lung, ovarian, prostate cancers, mesothelioma and glioblastoma. The company collaborates with various pharmaceutical companies to expand its products and technology platforms. Aduro BioTech is headquartered in Berkeley, California, the US.

Aduro BioTech Inc (ADRO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aduro BioTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13

Venture Financing 15

Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15

Aduro BioTech Raises USD55 Million in Series C Financing 17

Aduro BioTech Raises USD 7 Million In Venture Financing 18

Aduro BioTech Raises USD 6.5 Million In Venture Financing 19

BioNovion Raises Funds through Venture Financing 20

Partnerships 21

Aduro BioTech Enters into Agreement with Immunotherapeutics and Vaccine Research Initiative 21

HitGen Enters into Agreement with Aduro Biotech 22

Aduro Biotech Expands Agreement with Merck 23

University of California, Berkeley Enters into Agreement with Aduro Biotech 24

Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 25

BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 26

Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 27

Licensing Agreements 29

Aduro BioTech Enters into Licensing Agreement with Stanford University 29

Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 30

Merck Enters into Licensing Agreement with BioNovion 31

Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 32

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 34

Aduro BioTech Enters Into Licensing Agreement With University Of California, Berkeley 35

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 36

Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University for GVAX-Related Patent Rights 37

Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 38

Aduro BioTech Enters into Licensing Agreement with UCB 39

Equity Offering 40

Aduro Biotech Plans to Raise Funds through Public Offering of Shares 40

Aduro Biotech Plans to Raise up to USD100 Million in Public Offering of Shares 41

Aduro Biotech to Raise up to USD100 Million in Public Offering of Shares 42

Aduro BioTech Raises USD25 Million in Private Placement Shares 43

Aduro BioTech Raises USD136.8 Million in IPO 44

Acquisition 46

Aduro Biotech Acquires BioNovion 46

Aduro BioTech Inc-Key Competitors 47

Aduro BioTech Inc-Key Employees 48

Aduro BioTech Inc-Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Recent Developments 50

Financial Announcements 50

Oct 30, 2018: Aduro Biotech reports third quarter 2018 financial results 50

Aug 01, 2018: Aduro Biotech reports second quarter 2018 financial results 51

May 02, 2018: Aduro Biotech Announces First Quarter 2018 Financial Results 52

Mar 01, 2018: Aduro Biotech Reports Fourth Quarter And Full Year 2017 Financial Results 53

Oct 31, 2017: Aduro Biotech Reports Third Quarter 2017 Financial Results 54

Aug 02, 2017: Aduro Biotech Reports Second Quarter 2017 Financial Results 55

May 02, 2017: Aduro Biotech Reports First Quarter 2017 Financial Results 56

Mar 01, 2017: Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results 57

Corporate Communications 59

Sep 19, 2018: Aduro Biotech Announces the Departure of Natalie R. Sacks 59

Jan 05, 2018: Aduro Biotech Announces Management Changes 60

Jul 27, 2017: Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017 61

Apr 20, 2017: Aduro Biotech Announces Management Promotions 62

Product News 63

12/18/2017: Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma 63

12/12/2017: Aduro Biotech Provides Update on CRS-207 Programs 64

09/04/2018: Aduro Biotech and Dana-Farber Cancer Institute publish data highlighting immunosuppressive impact of APRIL in multiple myeloma in leukemia 65

03/06/2017: Aduro Biotech Presents Data On BION-1301 at the 2017 American Association for Cancer Research Annual Meeting 66

03/06/2017: Aduro Biotech Presents Data on Vaccine Technology targeting STING at the 2017 American Association for Cancer Research Annual Meeting 67

Clinical Trials 68

Sep 04, 2018: Aduro Biotech presents preclinical data for BION-1301, a first-in-class antibody targeting human APRIL, at the 2018 European Congress of Immunology 68

Apr 17, 2018: Aduro Biotech Presents Preclinical Data of ADU-1604 at the American Association for Cancer Research Annual Meeting 69

Apr 17, 2018: Aduro Biotech Presents Preclinical Data of BION-1301 at the American Association for Cancer Research Annual Meeting 70

Mar 14, 2018: Aduro Biotech to Present Preclinical Data on ADU-1604 at AACR 2018 Annual Meeting 71

Mar 14, 2018: Aduro Biotech to Present Preclinical Data on BION-1301 at AACR 2018 Annual Meeting 72

Nov 10, 2017: Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604 73

Nov 01, 2017: Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting 74

Sep 27, 2017: Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology 75

Aug 09, 2017: Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents 76

Jun 29, 2017: Aduro Biotech Announces Initiation of Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Previously-Treated Gastroesophageal Adenocarcinoma 77

Jun 28, 2017: Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA for the Treatment of Patients with Previously Treated Malignant Pleural Mesothelioma 78

May 26, 2017: Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting 79

Appendix 80

Methodology 80

About GlobalData 80

Contact Us 80

Disclaimer 80


List Of Figure

List of Figures

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aduro BioTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aduro BioTech Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13

Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15

Aduro BioTech Raises USD55 Million in Series C Financing 17

Aduro BioTech Raises USD 7 Million In Venture Financing 18

Aduro BioTech Raises USD 6.5 Million In Venture Financing 19

BioNovion Raises Funds through Venture Financing 20

Aduro BioTech Enters into Agreement with Immunotherapeutics and Vaccine Research Initiative 21

HitGen Enters into Agreement with Aduro Biotech 22

Aduro Biotech Expands Agreement with Merck 23

University of California, Berkeley Enters into Agreement with Aduro Biotech 24

Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 25

BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 26

Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 27

Aduro BioTech Enters into Licensing Agreement with Stanford University 29

Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 30

Merck Enters into Licensing Agreement with BioNovion 31

Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 32

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 34

Aduro BioTech Enters Into Licensing Agreement With University Of California, Berkeley 35

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 36

Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University for GVAX-Related Patent Rights 37

Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 38

Aduro BioTech Enters into Licensing Agreement with UCB 39

Aduro Biotech Plans to Raise Funds through Public Offering of Shares 40

Aduro Biotech Plans to Raise up to USD100 Million in Public Offering of Shares 41

Aduro Biotech to Raise up to USD100 Million in Public Offering of Shares 42

Aduro BioTech Raises USD25 Million in Private Placement Shares 43

Aduro BioTech Raises USD136.8 Million in IPO 44

Aduro Biotech Acquires BioNovion 46

Aduro BioTech Inc, Key Competitors 47

Aduro BioTech Inc, Key Employees 48

Aduro BioTech Inc, Other Locations 49

Aduro BioTech Inc, Subsidiaries 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Aduro BioTech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.